当前位置:
X-MOL 学术
›
Cancer Discov.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Bemarituzumab Is Active in FGFR2b-High Gastroesophageal Adenocarcinoma.
Cancer Discovery ( IF 28.2 ) Pub Date : 2020-05-01 , DOI: 10.1158/2159-8290.cd-rw2020-045 American Association for Cancer Research
Cancer Discovery ( IF 28.2 ) Pub Date : 2020-05-01 , DOI: 10.1158/2159-8290.cd-rw2020-045 American Association for Cancer Research
The FGFR2b inhibitor bemarituzumab was effective in high-FGFR2b gastroesophageal adenocarcinoma.
中文翻译:
贝马妥珠单抗在FGFR2b-高胃食管腺癌中活跃。
FGFR2b抑制剂贝马妥珠单抗对高FGFR2b胃食管腺癌有效。
更新日期:2020-05-01
中文翻译:
贝马妥珠单抗在FGFR2b-高胃食管腺癌中活跃。
FGFR2b抑制剂贝马妥珠单抗对高FGFR2b胃食管腺癌有效。